News/events
Press Releases
| 10/26/2011 | | KemPharm, Inc. Expands Pain Therapy Pipeline with Discovery of KP511 |
| 8/30/2011 | | KemPharm, Inc. Expands ADHD Pipeline with Discovery of KP415 |
| 5/24/2011 | | KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain |
| 4/25/2011 | | KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD |
| 3/1/2011 | | KemPharm, Inc. Files Antitrust and Other Counterclaims against Shire LLC |
| 2/22/2011 | | KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP201 for Pain |
| 8/25/2010 | | KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company’s ADHD Prodrug Technology |
| 8/16/2010 | | KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Company's ADHD Prodrug Technology |
| 6/23/2010 | | KemPharm, Inc. Appoints Todd Johnson, Ph.D. as Chief Commercial Officer |
| 5/18/2010 | | KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201 |
| 1/11/2010 | | KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD |
| 10/22/2009 | | KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD |
| 9/16/2009 | | KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing |
KemPharm News
Recent/Upcoming Events
|
|
